Expert consensus on diagnosis and treatment of drug-resistant spinal tuberculosis

doi:10.3969/j.issn.1000-6621.2019.04.003

Abstract

Abstract:

Drug-resistant tuberculosis is a difficult problem in the field of TB treatment.Spinal tuberculosis is a common extrapulmonary secondary tuberculosis. Drug resistance seriously affects the therapeutic effect and prognosis of spinal tuberculosis.This expert consensus provides a brief introduction to the definition and epidemiology of drug-resistant spinal tuberculosis, proposes the diagnostic criteria and methods of drug-resistant spinal tuberculosis, puts forward some suggestions on the formulation of anti-tuberculosis treatment, the choice of surgical timing and surgical methods, prospects the research development of drug-resistant spinal tuberculosis in the future.

Key words: Tuberculosis, spinal, Tuberculosis, multidrug-resistant, Diagnostic techniques and procedures, Surgical procedures, elective, Combined modality therapy, Clinical protocols

consensus on diagnosis and treatment of drug-resistant spinal tuberculosis writing group Expert. Expert consensus on diagnosis and treatment of drug-resistant spinal tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(4): 377-382. doi: 10.3969/j.issn.1000-6621.2019.04.003

Figures/Tables 2

References 32

[1]	Cox HS, Niemann S, Ismailov G , et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis, 2007,44(11):1421-1427. doi: 10.1086/517536 URL pmid: 17479936
[2]	World Health Organization. Global tuberculosis report 2015. Geneva:World Health Organization, 2015.
[3]	Keshavjee S, Farmer PE . Tuberculosis,drug resistance,and the history of modern medicine. N Engl J Med, 2012,367(10):931-936. doi: 10.1056/NEJMra1205429 URL
[4]	World Health Organization. Global tuberculosis report 2016. Geneva:World Health Organization, 2016.
[5]	许宾, 孙加源, 黄燕 . 综合医院肺外结核101例临床分析. 中国防痨杂志, 2004,26(3):151-154. doi: 10.3969/j.issn.1000-6621.2004.03.008 URL
[6]	Yoon HJ, Song YG, Park WI , et al. Clinical manifestatians and diagnosis of extrapulmonary tuberculosis. Yonsei Med J, 2004,45(3):453-461. doi: 10.3349/ymj.2004.45.3.453 URL pmid: 15227732
[7]	李强, 董伟杰, 范俊 , 等. 38例骨关节结核患者病灶标本分枝杆菌培养及药物敏感性试验结果分析. 中国防痨杂志, 2017,39(3):277-281. doi: 10.3969/j.issn.1000-6621.2017.03.015 URL
[8]	张娟, 蒋俊, 张红 , 等. MGIT960 与罗氏培养法在结核分枝杆菌培养及药敏试验中的比对分析. 中国防痨杂志, 2011,33(6):361-365.
[9]	许宏涛, 陈东科, 赖惠英 . 结核分枝杆菌四种常用方法检测比较. 中国热带医学, 2015,15(5):612-614.
[10]	范顺武, 胡子昂 . 重视脊柱结核化学药物治疗的重要性. 中国骨伤, 2017,30(9):783-786. doi: 10.3969/j.issn.1003-0034.2017.09.001 URL
[11]	Tan Y, Li Q, Wang Q , et al. Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China. Sci Rep, 2017,7(1):3364. doi: 10.1038/s41598-017-03473-7 URL pmid: 28611407
[12]	Rufai SB, Kumar P, Singh A , et al. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis. J Clin Microbiol, 2014,52(6):1846-1852. doi: 10.1128/JCM.03005-13 URL pmid: 4042801
[13]	Wang G, Dong W, Lan T , et al. Diagnostic accuracy evaluation of the conventional and molecular tests for spinal tuberculosis in a cohort, head-to-head study. Emerg Microbes Infect, 2018,7(1):109. doi: 10.1038/s41426-018-0114-1 URL
[14]	Li Y, Jia W, Lei G , et al. Diagnostic efficiency of Xpert MTB/RIF assay for osteoarticular tuberculosis in patients with inflammatory arthritis in China. PLoS One, 2018,13(6):e0198600. doi: 10.1371/journal.pone.0198600 URL pmid: 29856840
[15]	穆晶, 赵丹, 董宇杰 , 等. 结核病病理学诊断的研究进展与临床应用. 结核病与肺部健康杂志, 2017,6(4):386-390.
[16]	Valafar F .Pathogenesis of multi drug-resistant and extensively drug-resistant tuberculosis as a determinant of future treatment success.Int J Mycobacteriol, 2016,5 Suppl 1: S64-65. doi: 10.1016/j.ijmyco.2016.11.017 URL pmid: 28043618
[17]	Rahman MA, Sarkar A . Extensively drug-resistant tuberculosis (XDR-TB):A daunting challenge to the current End TB Strategy and policy recommendations. Indian J Tuberc, 2017,64(3):153-160. doi: 10.1016/j.ijtb.2017.03.006 URL
[18]	秦世炳 . 重视结核病诊治和脊柱结核手术时机的选择. 中国骨伤, 2013,26(7):533-535. doi: 10.3969/j.issn.1003-0034.2013.07.001 URL
[19]	Pang Y, Lu J, Huo F ,et al.Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China:A five-year review. J Infect, 2017,75(5):433-440. doi: 10.1016/j.jinf.2017.08.005 URL pmid: 28804028
[20]	World Health Organization. Treatment guidelines for drug-resistant tuberculosis,2016 update. Geneva:World Health Organization, 2016. URL pmid: 27748093
[21]	宋向伟, 梁强, 马文鑫 , 等. 影响脊柱结核术后超短程化疗方案的因素分析. 中国矫形外科杂志, 2018,26(2):144-149. doi: 10.3977/j.issn.1005-8478.2018.02.10 URL
[22]	姚晓伟, 董昭良, 李卓 , 等. 60例耐药脊柱结核患者个体化治疗及疗效的临床研究. 中国防痨杂志, 2016,38(11):978-984. doi: 10.3969/j.issn.1000-6621.2016.11.017 URL
[23]	习昕 . 肺外结核514例临床分析. 广州:中山大学, 2006.
[24]	牟朋林, 陈克冰, 杨建惠 . 脊柱结核术后复治的危险因素Logistic回归分析. 现代医院, 2018,18(5):719-721,724.
[25]	秦世炳 . 重视肺外结核病并规范骨关节结核的临床诊治. 中国防痨杂志, 2014,36(8):655-658. doi: 10.3969/j.issn.1000-6621.2014.08.011
[26]	马远征 . 进一步提高脊柱结核的治疗效果. 中国脊柱脊髓杂志, 2010,20(10):795-796. doi: 10.3969/j.issn.1004-406X.2010.10.02 URL
[27]	马远征, 李大伟, 胡明马 , 等. 耐药脊柱结核个体化诊疗模式应用研究//中华医学会骨科分会.中华医学会第十四届骨科学术会议暨第七届COA国际学术大会资料汇编. 北京:中华医学会骨科分会, 2012.
[28]	许建中 . 规范脊柱结核治疗,为我国结核病防治做出更大贡献. 中华骨科杂志, 2014,34(2):97-101. doi: 10.3760/cma.j.issn.0253-2352.2014.02.001
[29]	张宏其 . 如何全面认识和规范应用单纯经后路病灶清除椎体间植骨术治疗脊柱结核. 中国矫形外科杂志, 2018,26(2):97-100.
[30]	蒋之, 屈满英, 万轲 . 耐药脊柱结核的临床分析及疗效研究. 中国现代医学杂志, 2016,11(6):132-136. doi: 10.3969/j.issn.1005-8982.2016.11.029 URL
[31]	李大伟, 马远征, 李力韬 , 等. 脊柱结核伴截瘫外科治疗的疗效分析. 中华骨科杂志, 2014,34(2):156-161. doi: 10.3760/cma.j.issn.0253-2352.2014.02.010 URL
[32]	张宏其, 陈筱, 郭虎兵 , 等. 单纯后路病灶清除椎体间植骨融合内固定治疗脊柱结核的适应证及疗效评价. 中国矫形外科杂志, 2012,20(3):196-199. doi: 10.3977/j.issn.1005-8478.2012.03.02 URL

脊柱结核患者类别	2015年	2016年	2017年
非耐药例数	572	586	553
单耐药例数	4	10	3
耐多药例数	6	8	38
多耐药例数	1	2	2
初治耐药例数	0	2	4
复治耐药例数	11	18	39

药物名称	2015年			2016年			2017年
药物名称	检测例数	耐药例数	耐药率 (%)	检测例数	耐药例数	耐药率 (%)	检测例数	耐药例数	耐药率 (%)
异烟肼	594	10	1.7	626	16	2.6	639	16	2.5
利福平	594	9	1.5	626	20	3.2	639	20	3.1
链霉素	487	5	1.0	389	9	2.3	639	12	1.9
利福喷丁	594	8	1.3	626	13	2.1	639	11	1.7
利福布汀	594	8	1.3	626	13	2.1	639	10	1.6
对氨基水杨酸-异烟肼	487	2	0.4	389	7	1.8	639	6	0.9
丙硫异烟胺	487	1	0.2	389	2	0.5	639	3	0.5
阿米卡星	487	2	0.4	389	2	0.5	639	3	0.5
左氧氟沙星	487	2	0.4	389	3	0.8	639	3	0.5
莫西沙星	-	-	-	389	3	0.8	639	3	0.5
卷曲霉素	487	2	0.4	389	2	0.5	639	3	0.5
氯法齐明	-	-	-	389	5	1.3	639	3	0.5
克拉霉素	-	-	-	389	2	0.5	-	-	-
乙胺丁醇	-	-	-	626	4	0.6	-	0	-